Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis.

ABSTRACT: The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-, mechanical ventilation-, and vasopressor-free days at day 28 and development of secondary infections.

Design

Retrospective, observational, multicenter, cohort study between March 15, 2020, and May 31, 2020. Using propensity score matching based on ICU admission source, C-reactive protein, Sequential Organ Failure Assessment score, vasopressor use, age, race, weight, and mechanical ventilation, patients who received tocilizumab were matched to patients who did not receive tocilizumab.

Setting

Ten hospitals within the Cleveland Clinic Ent

SUBMITTER: Rajendram P 

PROVIDER: S-EPMC7808529 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature